Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273

Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase vaccination coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about the...

Descripción completa

Detalles Bibliográficos
Autores: Laboratorio SeVa Group, Ministerio de Salud de la Provincia de Córdoba Group, Universidad Nacional de Córdoba. Facultad Ciencias Médicas-InViV Group, Ministerio de Salud de la Provincia de La Rioja Group, Ministerio de Salud de la Provincia de San Luis Group, Universidad Nacional de La Plata Group, Ministerio de Salud de la Provincia de Buenos Aires Group, Pascuale, Carla Antonela, Varese, Augusto, Ojeda, Diego Sebastian, Pasinovich, Marina E., Lopez, Laura, Rossi, Andrés Hugo, Rodriguez, Pamela Elizabeth, Miglietta, Esteban Alberto, Mazzitelli, Ignacio Gabriel, Di Diego García, Facundo, Sanchez, Lautaro Nicolas, Oviedo Rouco, Santiago, González López Ledesma, María Mora, Zurano, Juan Pablo, Mazzitelli, Bianca, Scruzzi, Graciela Fabiana, Barbero, Paula, Cardozo, Diego, Gallego, Sandra Veronica, Borda, Mariel Alejandra, Diaz, Miguel, Ridao, Francisco, Brigido Rosales, Angela, Bhon, Jorge, Talia, Juan Manuel, Diangelo, María E., Lacaze, María A., Aime, Balanzino, Gutierrez, Sebastian Isaac, Ercole, Regina, Ferreyra Compagnucci, Malena María, Echegoyen, Cecilia Vanina, Hozbor, Daniela Flavia, Docena, Guillermo H., Pifano, Marina, Geffner, Jorge Raúl, Gamarnik, Andrea Vanesa, Spinsanti, Lorena Ivana, Beranek, Mauricio Daniel, Jofre, Claudio Francisco, Pizzi, Rogelio Daniel, Konigheim, Brenda Salome, Blanco, Sebastian
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:Argentina
Institución:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/215983
Acceso en línea:http://hdl.handle.net/11336/215983
Access Level:acceso abierto
Palabra clave:SARS-COV-2
HETEROLOGOUS VACCINATION
COVID-19
VACCINATION COVERAGE
https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
Descripción
Sumario:Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase vaccination coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about the combination of these platforms with other vaccines widely used in developing countries, such as BBIBP-CorV and Sputnik V. Here, we assess the immunogenicity and reactogenicity of 15 vaccine combinations in 1,314 participants. We evaluate immunoglobulin G (IgG) anti-spike response and virus neutralizing titers and observe that a number of heterologous vaccine combinations are equivalent or superior to homologous schemes. For all cohorts in this study, the highest antibody response is induced by mRNA-1273 as the second dose. No serious adverse events are detected in any of the schedules analyzed. Our observations provide rational support for the use of different vaccine combinations to achieve wide vaccine coverage in the shortest possible time.

Similares en LA Referencia